Portal de recerca
Coste-efectividad de la oxigenoterapia de alto flujo en el tratamiento de la neumonía por SARS-CoV-2.
Data de publicació:
Data Ahead of Print:
Autors de IIS La Fe
Autors aliens a IIS La Fe
- Gonzalez-Castro, A
- Cuenca Fito, E
- Fernandez, A
- Peñasco Y
- Medina Villanueva, A
- Fajardo, A
- Escude-Acha, P
Abstract
INTRODUCTION: high-oxygen nasal cannulas in patients with respiratory failure secondary to SARS-CoV-2 pneumonia have not been studied from a cost-effectiveness point of view. METHODS: Retrospective analysis of patients who had entered the COVID-area of an intensive medicine service in a third reference hospital, between March-December 2020. An effectiveness cost analysis was carried out comparing 2therapeutic decisions: the experimental strategy was defined as a mixed strategy consisting of the initial application of high flow nasal oxygen (HFNO) and application of VMI only to HFNO failures. The optimal rational decision was defined as maximizing expected profit, and economic efficiency was assessed by calculating the Incremental Cost-Effectiveness Ratio (ICER) for years of life gained. RESULTS: Of the 185 patients tested, 101 (55%) received invasive mechanical ventilation immediately and 84 (45%) were treated with HFNO at the outset. In the cost-effectiveness analysis, comparing both therapeutic strategies, the probability that the experimental strategy would be more effective was 0.974, reaching statistical significance: Difference in average proportions -0.113; 95% CI:-0.018 to -0.208. This corresponds to an NNT of 9 patients. The optimal decision was HFNO's strategy followed by VMI in HFNO failures. This option had an RCEI of 5582 euros per year of life gained. CONCLUSIONS: It is important to establish in the future reliable markers in the use of HFNO so that this therapy improves its cost-effective benefits.
Copyright © 2022 FECA. Publicado por Elsevier España, S.L.U. All rights reserved.
Dades de la publicació
- ISSN/ISSNe:
- 2603-6479, 2603-6479
- Tipus:
- Article
- Pàgines:
- 152-157
- PubMed:
- 36400703
- Factor d'Impacte:
- 0,169 SCImago ℠
- Quartil:
- Q4 SCImago ℠
Journal of Healthcare Quality Research Elsevier Espana
Documents
- No hi ha documents
Filiacions
Keywords
- COVID-19; Cost-effectiveness; Coste-efectividad; Neumonía; Pneumonia; SARS-CoV-2
Projectes associats
ESTUDIO MULTICÉNTRICO DE FASE 3, ALEATORIZADO, CON GRUPOS PARALELOS, ENMASCARADO PARA EL INVESTIGADOR, PARA INVESTIGAR LA SEGURIDAD Y LA EFICACIA DE FIDAXOMICINA EN SUSPENSIÓN ORAL O COMPRIMIDOS CADA 12 HORAS, Y VANCOMICINA EN SOLUCIÓN ORAL O CÁPSULAS CADA 6 HORAS DURANTE 10 DÍAS, EN SUJETOS PEDIÁTRICOS CON DIARREA ASOCIADA A CLOSTRIDIUM DIFFICILE.
Investigador Principal: ANA ISABEL PIQUERAS ARENAS
2819-CL-0202 . 2015
ESTUDIO SIMPLE CIEGO, ALEATORIZADO, MULTICÉNTRICO, CON CONTROL ACTIVO PARA EVALUAR LA SEGURIDAD, TOLERABILIDAD, FARMACOCINÉTICA Y EFICACIA DE CEFTAZIDIMA Y AVIBACTAM CUANDO SE PROPORCIONAN CON METRONIDAZOL EN COMPARACIÓN CON MEROPENEM EN NIÑOS DE 3 MESES A MENOS DE 18 AÑOS DE EDAD CON INFECCIONES INTRAABDOMINALES COMPLICADAS (IIACS).
Investigador Principal: EMILIO MONTEAGUDO MONTESINOS
D4280C00015 . 2015
EFICACIA Y SEGURIDAD DE LEVOSIMENDAN EN EL FALLO CARDIACO AGUDO GRAVE EN NIÑOS CRITICOS
Investigador Principal: VICENT MODESTO ALAPONT
LEVOPED1
ESTUDIO ALEATORIZADO CON CONTROL ACTIVO PARA COMPARAR LA EFICACIA Y LA SEGURIDAD DEL ISOFLURANO INHALADO ADMINISTRADO POR EL ANACONDA-S (DISPOSITIVO DE CONSERVACIÓN DE ANESTÉSICO) CON EL MIDAZOLAM INTRAVENOSO PARA LA SEDACIÓN EN PACIENTES PEDIÁTRICOS CON VENTILACIÓN MECÁNICA DE ENTRE 3 Y 17 AÑOS (MENOS DE 18 AÑOS) SED002.
Investigador Principal: JUAN ENCARNACION MARTINEZ
SED002 . 2021